Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation

Marios Dimitriou, Teresa Mortera-Blanco, Magnus Tobiasson, Stefania Mazzi, Madeleine Lehander, Kari Högstrand, Mohsen Karimi, Gunilla Walldin, Monika Jansson, Sofie Vonlanthen, Per Ljungman, Saskia Langemeijer, Tetsuichi Yoshizato, Eva Hellström-Lindberg, Petter S. Woll, Sten Eirik W. Jacobsen

Blood (2024) 143 (11): 953–966.

https://doi.org/10.1182/blood.2023022851

Published: 2024

Includes: Supplemental data

Journal Articles

From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival

Jakob Werner Hansen, MD, Morten Munk Johansen, MD, Maj Karoline Westman, MSc, Leonie Saft, MD PhD, Lene Dissing Sjö, MD PhD, Claus Werenberg Marcher, MD PhD, Mette Skov Holm, MD PhD, Marios Dimitriou, PhD, Mohsen Karimi, PhD, Klas Raaschou-Jensen, MD, Andreas Birkedal Glenthøj, MD PhD, Marianne Tang Severinsen, MD PhD, Eva Hellström-Lindberg, MD PhD, Mette Klarskov Andersen, MD DMSc, Kirsten Grønbæk, Professor, MD DMSc

Blood (2018) 132 (Supplement 1): 794.

https://doi.org/10.1182/blood-2018-99-110767

Published: 2018

Journal Articles

Gene expression and risk of leukemic transformation in myelodysplasia

Yusuke Shiozawa, Luca Malcovati, Anna Gallì, Andrea Pellagatti, Mohsen Karimi, Aiko Sato-Otsubo, Yusuke Sato, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hideki Makishima, Jacqueline Boultwood, Eva Hellström-Lindberg, Satoru Miyano, Mario Cazzola, Seishi Ogawa

Blood (2017) 130 (24): 2642–2653.

https://doi.org/10.1182/blood-2017-05-783050

Published: 2017

Includes: Supplemental data

Journal Articles

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Andreas T Björklund, MD PhD MSc, Mattias Carlsten, MD PhD, Ebba Sohlberg, PhD, Trevor Clancy, Lisa Liu, Mohsen Karimi, PhD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Emma Watz, Björn Engelbrekt Wahlin, Marzia Palma, MD PhD, Lotta Hansson, Per Ljungman, Eva Hellstrom-Lindberg, MD PhD, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4458.

https://doi.org/10.1182/blood.V130.Suppl_1.4458.4458

Published: 2017

Journal Articles

SF3B1 -initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

Teresa Mortera-Blanco, Marios Dimitriou, Petter S. Woll, Mohsen Karimi, Edda Elvarsdottir, Simona Conte, Magnus Tobiasson, Monika Jansson, Iyadh Douagi, Matahi Moarii, Leonie Saft, Elli Papaemmanuil, Sten Eirik W. Jacobsen, Eva Hellström-Lindberg

Blood (2017) 130 (7): 881–890.

https://doi.org/10.1182/blood-2017-03-776070

Published: 2017

Includes: Supplemental data

Journal Articles

Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations

Christian Scharenberg, MD, Petter S. Woll, PhD, Valentina Giai, MD PhD, Andrea Pellagatti, PhD, Leonie Saft, MD PhD, Marios Dimitriou, Martin Jädersten, Monika Jansson, Iyadh Douagi, PhD, Donna S. Neuberg, ScD, Mohsen Karimi, Katarina Le Blanc, MD, PhD, Jacqueline Boultwood, PhD, Sten Eirik Jacobsen, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2016) 128 (22): 4329.

https://doi.org/10.1182/blood.V128.22.4329.4329

Published: 2016

Journal Articles

Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

Magnus Tobiasson, MD, Donal McLornan, MDPhD, Mohsen Karimi, Marios Dimitriou, PhD, Monika Jansson, Asmaa Ben Azenkoud, Martin Jädersten, Greger Lindberg, Hani Abdulkadir, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Johanna Ungerstedt, Associate Professor, Andreas Lennartsson, Karl Ekwall, Ghulam J Mufti, Eva Hellström-Lindberg, MD PhD

Blood (2015) 126 (23): 2839.

https://doi.org/10.1182/blood.V126.23.2839.2839

Published: 2015

Journal Articles

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Blood (2015) 126 (2): 233–241.

https://doi.org/10.1182/blood-2015-03-633537

Published: 2015

Includes: Supplemental data

Journal Articles

Characterization of the Hematopoietic Stem and Progenitor Cell Hierarchy in Myelodysplastic Syndromes Patients with Monosomy 7 As the Sole Cytogenetic Abnormality

Marios Dimitriou, Teresa Mortera-Blanco, Petter S Woll, PhD, Mohsen Karimi, Helen Doolittle, MD, Sten Eirik W Jacobsen, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2014) 124 (21): 3490.

https://doi.org/10.1182/blood.V124.21.3490.3490

Published: 2014

Journal Articles

Mutations in Histone Modulators and HOXA5 Methylation Levels Affects Survival in Azacitidine Treated MDS Patients

Magnus Tobiasson, MD, Mohsen Karimi, Marios Dimitriou, Ying Qu, MDM.Sc, Andreas Lennartsson, PhD, Hani Abdulkadir Ali, Ashwin Unnikrishnan, PhD, Martin Jadersten, MDPhD, Monika Jansson, Asmaa Ben Azenkoud, John E Pimanda, MD PhD, Karl Ekwall, Prof, Johanna Ungerstedt, MD PhD, Soren Lehmann, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2014) 124 (21): 4613.

https://doi.org/10.1182/blood.V124.21.4613.4613

Published: 2014

Journal Articles

Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts

Blood (2014) 124 (21): 825.

https://doi.org/10.1182/blood.V124.21.825.825

Published: 2014

Journal Articles

Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation

Michelle Rönnerblad, Robin Andersson, Tor Olofsson, Iyadh Douagi, Mohsen Karimi, Sören Lehmann, Ilka Hoof, Michiel de Hoon, Masayoshi Itoh, Sayaka Nagao-Sato, Hideya Kawaji, Timo Lassmann, Piero Carninci, Yoshihide Hayashizaki, Alistair R. R. Forrest, Albin Sandelin, Karl Ekwall, Erik Arner, Andreas Lennartsson

Blood (2014) 123 (17): e79–e89.

https://doi.org/10.1182/blood-2013-02-482893

Published: 2014

Includes: Supplemental data

Journal Articles

Erythropoiesis In SF3B1 Mutated RARS Is Disrupted During Terminal Erythroid Maturation

Simona Conte, Liselotte Vesterlund, PhD, Shintaro Katayama, PhD, Mohsen Karimi, PhD, Elli Papaemmanuil, PhD, Monika Jansson, Teresa Mortera-Blanco, PhD, Marios Dimitriou, PhD, Birgitta Sander, MD, PhD, Tiina Skoog, Peter J. Campbell, PhD, Juha Kere, MD, PhD, Per Unneberg, PhD, Eva Hellström-Lindberg, MD, PhD

Blood (2013) 122 (21): 2408.

https://doi.org/10.1182/blood.V122.21.2408.2408

Published: 2013

Journal Articles

Hierarchical Analysis Of Recurrent Point Mutations In SF3B1 and TET2 In RARS Stem Cells

Teresa Mortera-Blanco, PhD, Marios Dimitriou, PhD, Petter Woll, PhD, Mohsen Karimi, PhD, Elli Papaemmanuil, PhD, Simona Conte, Oni Chowdhuri, Monika Jansson, Peter J. Campbell, PhD, Sten Eirik W Jacobsen, PhD, Eva Hellström-Lindberg, MD, PhD

Blood (2013) 122 (21): 2749.

https://doi.org/10.1182/blood.V122.21.2749.2749

Published: 2013

Journal Articles

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Marianne B. Treppendahl, MD, Magnus Tobiasson, MD, Anni Aggerholm, PhD, Mohsen Karimi, PhD, Trine Silkjaer, MD, Lone S. Friis, MD, PhD, Mette K. Andersen, PhD, Lars Kjeldsen, MD, PhD, Mette S. Holm, MD, PhD, Eva Hellström-Lindberg, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 2394.

https://doi.org/10.1182/blood.V120.21.2394.2394

Published: 2012

Journal Articles

Genome-Wide DNA Methylation Analysis Shows Enrichment of Differential Methylation in “Open Seas” and Enhancers and Reveals Hypomethylation in DNMT3A Mutated Cytogenetically Normal AML (CN-AML)

Ying Qu, MD, M.Sc, Andreas Lennartsson, PhD, Verena I. Gaidzik, MD, Ph.D, Stefan Deneberg, MD, Ph.D, Sofia Bengtzén, Mohsen Karimi Arzenani, PhD, Lars Bullinger, MD, PhD, Konstanze Döhner, MD, Ph.D, Sören Lehmann, MD, PhD

Blood (2012) 120 (21): 653.

https://doi.org/10.1182/blood.V120.21.653.653

Published: 2012

Journal Articles

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Stefan Deneberg, Philippe Guardiola, Andreas Lennartsson, Ying Qu, Verena Gaidzik, Odile Blanchet, Mohsen Karimi, Sofia Bengtzén, Hareth Nahi, Bertil Uggla, Ulf Tidefelt, Martin Höglund, Christer Paul, Karl Ekwall, Konstanze Döhner, Sören Lehmann

Blood (2011) 118 (20): 5573–5582.

https://doi.org/10.1182/blood-2011-01-332353

Published: 2011

Includes: Supplemental data

NARROW

Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation

From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival

Gene expression and risk of leukemic transformation in myelodysplasia

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

SF3B1 -initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations

Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Characterization of the Hematopoietic Stem and Progenitor Cell Hierarchy in Myelodysplastic Syndromes Patients with Monosomy 7 As the Sole Cytogenetic Abnormality

Mutations in Histone Modulators and HOXA5 Methylation Levels Affects Survival in Azacitidine Treated MDS Patients

Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts

Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation

Erythropoiesis In SF3B1 Mutated RARS Is Disrupted During Terminal Erythroid Maturation

Hierarchical Analysis Of Recurrent Point Mutations In SF3B1 and TET2 In RARS Stem Cells

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Genome-Wide DNA Methylation Analysis Shows Enrichment of Differential Methylation in “Open Seas” and Enhancers and Reveals Hypomethylation in DNMT3A Mutated Cytogenetically Normal AML (CN-AML)

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only